An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

Inclusion Criteria: * Adult patients, \>/= 18 years of age * B cell-lineage chronic lymphocytic leukaemia (B-CLL) * Prescribed with MabThera/Rituxan in combination with chemotherapy according to the approved SMPC * Informed consent to data collection Exclusion Criteria: * Treatment with any marketed or non-marketed drug substance or experimental therapy within 4 weeks prior to first dose of study drug or participation in a clinical trial within 30 days prior to entering this study * Any other tumour disease